SecBot SecBot

REGN drug pipeline

$955.47
+0.5% 1-day · Nov 13
Next catalyst
2026
Otarmeni BLA filing
Typical move on FDA news
±1.8%
1-day, median of 22 events
IV rank
31
IV 33% · HV 47%
Rated drugs
17
2 bullish · 1 mixed · 14 neutral
Phase 3 trials
15
6 with results posted

Upcoming catalysts

3 dated
  1. Dec 3, 2026
    REGN7999
    Phase 2 primary completion
  2. Dec 22, 2026
    EYLEA HD
    Phase 3 primary completion
  3. 2026
    Otarmeni
    BLA filing

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (accelerated approval)
Time to marketAlready FDA-approved (April 23, 2026); commercially available in the U.S.

Otarmeni lunsotogene parvec Updated Jul 6

2026
Next catalyst
BLA filing · 2026
What to watch

Otarmeni's approval binary has passed and the drug is provided free in the U.S. under a government pricing deal, so it generates zero direct revenue. For Regeneron investors, EMA approval (under accelerated assessment review) is a modest upside tailwind but immaterial given the ultra-rare indication and free-access model. The stock's bigger catalysts are Eylea HD dosing expansions, the garetosmab PDUFA (August 2026), and Dupixent pipeline growth, not this drug.

Bull case
  • First and only FDA-approved gene therapy for genetic hearing loss, a historic first-in-class designation with no direct approved competitors for OTOF-related deafness (source: FDA press release).
  • Compelling efficacy data: 80% of children in the CHORD trial achieved hearing improvement to levels associated with natural hearing, with some patients reaching normal auditory thresholds (source: Regeneron press release via GlobeNewswire).
  • EMA acceptance for accelerated assessment review de-risks the European regulatory path and supports eventual global expansion.
Bear case
  • Zero-revenue model in the U.S., Regeneron provides Otarmeni free of charge, so this drug generates no direct sales or profit contribution, making it financially immaterial for a large-cap biotech (source: BioPharma Dive).
  • Ultra-rare indication with limited addressable market: OTOF gene mutations account for only 2-8% of inherited, non-syndromic congenital hearing loss cases, an estimated few thousand patients globally (source: FDA press release).
  • Accelerated approval carries post-marketing confirmatory trial requirements; failure to confirm clinical benefit could lead to withdrawal (source: Stocktwits/Regeneron disclosure).
▲ bullish
Impact
PhaseFiled/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
Time to marketIf the FDA approves on schedule, a U.S. launch could follow within weeks-to-months of the November 2026 PDUFA date; EU decision expected H2 2027, so EU commercialization is further out.

Cemdisiran Updated Aug 1

What to watch

Watch for the FDA decision on the cemdisiran gMG NDA around November 2026 (Priority Review), an approval would likely add a modest, first-in-class growth asset for REGN rather than a valuation-changing event, given the company's ~$73B market cap is driven mainly by Dupixent/EYLEA/Libtayo. Treat it as a pipeline tailwind, not a standalone thesis; also monitor the fianlimab securities class action (lead-plaintiff deadline September 14, 2026) as a separate overhang.

Bull case
  • Positive Phase 3 NIMBLE data: statistically significant and clinically meaningful improvements on primary and key secondary endpoints in gMG.
  • FDA accepted the NDA with Priority Review and a target action date of November 2026; EMA decision expected H2 2027.
  • Potential first-in-class siRNA for gMG with a convenient subcutaneous, ~4x-per-year dosing schedule, a differentiation and adherence story.
Bear case
  • Regulatory risk remains: a Priority Review NDA can still end in a Complete Response Letter or require more data; approval is not guaranteed.
  • gMG already has approved targeted biologic therapies, so cemdisiran must win on convenience, safety and price, a competitive market for a niche indication.
  • The catalyst is small relative to REGN's ~$73B valuation; historical cemdisiran NDA-submission catalysts moved REGN only about -1.4% and +0.6% (1-day), signaling limited share-price sensitivity.
▲ bullish
Impact
PhaseApproved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
Time to marketAlready approved and commercialized since 2017

Dupixent dupilumab Updated Jul 6

What to watch

Dupixent is Regeneron's most important revenue driver, generating collaboration revenue that rose 14-18% YoY in recent quarters. Investors should watch for the STYLE 1/STYLE 2 Phase 3 topline readouts for Lichen Simplex Chronicus (mid-2026) as the next label-expansion catalyst, but the main investor focus should be on Dupixent's patent cliff, earliest key patents begin expiring around 2027-2031, which will determine whether Regeneron can defend its ~$17.8B+ franchise against biosimilar entry.

Bull case
  • Unmatched label breadth: Dupixent is approved for 9 distinct indications (atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, COPD, CSU, bullous pemphigoid, AFRS), giving it a massive and growing addressable patient population across multiple specialties.
  • COPD approval (Sept 2024) opens a huge new market, analysts estimate $3.5B-$6.5B in peak COPD sales alone. Dupixent is the first-ever biologic approved for COPD, a disease affecting millions globally.
  • Growth trajectory remains strong: full-year 2025 global net sales rose 26% to ~$17.8B. Quarterly sales topped €4B for the first time in Q3 2025. The drug is projected to reach $22B+ in peak annual sales.
Bear case
  • Patent cliff looming: Dupixent's earliest key patents expire around 2027, with a web of patents extending to ~2031-2045. Amgen has reportedly retained litigation counsel to challenge Dupixent IL-4 receptor patents, and Sanofi/Regeneron filed a preemptive patent lawsuit. Biosimilar erosion is a medium-term existential threat to the franchise.
  • Safety litigation risk: A law firm launched a website in June 2026 targeting patients diagnosed with T-cell lymphoma after taking Dupixent, suggesting potential product liability litigation ahead.
  • Competitive pressure: Eli Lilly's lebrikizumab (Ebglyss), a targeted IL-13 inhibitor, is approved in the US and EU for atopic dermatitis, with in vitro studies suggesting higher binding affinity. While not a head-to-head threat yet, it narrows Dupixent's differentiation.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized since February 2021 (US) and June 2021 (EU). Latest label expansion (ages 1-5) approved September 2025.

Evkeeza evinacumab Updated Jul 6

What to watch

Evkeeza is a first-in-class ANGPTL3 inhibitor approved for an ultra-rare cholesterol disorder (HoFH, ~1,300 US patients). It is already de-risked by FDA approval but contributes only ~$130-150M in annual US sales versus Regeneron's ~$14.3B total revenue. The stock is primarily driven by Dupixent, EYLEA, and the broader pipeline, not this one drug. Watch quarterly Evkeeza US sales for gradual label-expansion uptake, but do not expect binary swings from this asset.

Bull case
  • First-in-class ANGPTL3 inhibitor with a differentiated mechanism from statins and PCSK9 inhibitors, no direct HoFH competitor with the same mechanism.
  • Progressive label expansion (12+ in 2021, 5-11 in 2023, 1-5 in Sept 2025) steadily broadens the addressable patient pool within the ~1,300 US HoFH population.
  • Pivotal Phase 3 data showed ~50% LDL-C reduction when added to standard therapy, a clinically meaningful efficacy signal in a high-unmet-need population.
Bear case
  • Ultra-rare indication (~1,300 US patients) inherently limits peak sales potential; even full penetration caps revenue at a few hundred million dollars annually.
  • Evkeeza contributed only ~$72.1M in US sales in H1 2025, roughly 1% of Regeneron's ~$14.3B total FY2025 revenue, making it essentially immaterial to the stock's direction.
  • The list price of ~$450K/year faces payer pushback; Canadian HTA analysis estimated a ~98% price reduction would be needed for cost-effectiveness at $50K/QALY.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and on the market (since August 2023)

EYLEA HD aflibercept Updated Jul 6

What to watch

EYLEA HD is a mature commercial asset, watch quarterly sales trends as a pulse check on how well Regeneron is defending share against Roche's Vabysmo and upcoming biosimilars (Samsung Bioepis Opuviz eligible Jan 2027). The real binary catalyst for REGN in the next 12 months is garetosmab's PDUFA in August 2026 for FOP. EYLEA HD's contribution is a gradual commercial story, not a binary event.

Bull case
  • EYLEA HD's extended dosing interval (up to every 20 weeks) is a meaningful competitive advantage over both the original EYLEA and some competitors, fewer injections is a strong selling point for patients and physicians.
  • Q1 2026 U.S. net sales of $468M were up 52% YoY, showing rapid uptake as patients and doctors transition from the original EYLEA to the higher-dose formulation.
  • The total addressable market for anti-VEGF eye drugs is large and growing, analysts project Vabysmo and EYLEA HD combined could generate $13.2B by 2030.
Bear case
  • Roche's Vabysmo (faricimab) continues to gain market share rapidly, it grew to ~CHF 3.9B in 2024 and Q2 2025 sales of CHF 1.05B were up 19% YoY, directly pressuring the EYLEA franchise.
  • Total EYLEA franchise (original + HD) global sales fell 17% in 2025 to $7.9B from $9.5B in 2024, and combined U.S. sales were down 28% YoY in Q3 2025.
  • Biosimilar competition is coming: Samsung Bioepis can launch Opuviz (aflibercept biosimilar) in the U.S. from January 2027, and Amgen's high-dose 8 mg biosimilar (ABP 938) is in Phase 3 trials.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized (first FDA approval Sept 2018)

Libtayo cemiplimab Updated Jul 6

What to watch

Libtayo is a solid commercial growth driver for Regeneron (~$1.5B in FY2025, +54% YoY in Q1 2026 to $438M), but it is one piece of a much larger story. The stock's next major moves will hinge on Dupixent growth, Eylea erosion from biosimilars, and pipeline events (like the May 2026 fianlimab melanoma failure), not on Libtayo-specific binary catalysts. Watch quarterly Libtayo revenue trends for commercial execution, but do not expect a drug-specific catalyst-driven swing in REGN shares from Libtayo in the near term.

Bull case
  • Libtayo revenue is growing rapidly, Q1 2026 global net product sales were $438M (+54% YoY), driven by the new adjuvant CSCC indication launch (source: Regeneron Q1 2026 earnings release via investor.regeneron.com).
  • Libtayo is the first and only immunotherapy approved for adjuvant CSCC (FDA Oct 2025, EU also approved), a first-mover advantage in a ~15,000-20,000 patient EU5 annual opportunity (source: flcube.com / Dermatology Times).
  • The Phase 3 C-POST trial showed a 68% reduction in recurrence or death risk in high-risk CSCC, a strong efficacy signal that supports label expansion and physician adoption (source: PharmExec via fda.gov link).
Bear case
  • Libtayo is a distant competitor in a PD-1 market utterly dominated by Merck's Keytruda (~$25B+ annually) and BMS's Opdivo (~$8B+). Libtayo's ~$1.5B is small by comparison and faces uphill share gains in NSCLC where Keytruda is entrenched (source: ainvest.com, fiercepharma.com).
  • The fianlimab (LAG-3) + Libtayo Phase 3 melanoma trial failed vs Keytruda in May 2026, causing REGN stock to drop ~10% in a single day, this highlights that Libtayo combo pipeline risk is real and negative readouts hit the stock hard (source: CNBC, Bloomberg, Regeneron investor news).
  • Regeneron and Sanofi withdrew the Libtayo cervical cancer sBLA in 2022/2024 after failing to align with FDA on post-marketing study requirements, limiting label expansion in a meaningful indication (source: Fierce Pharma, BioPharma Dive).
● neutral
Impact
PhaseApproved (Accelerated Approval)
Time to marketAlready approved and launching (FDA accelerated approval July 2025; EU conditional approval April 2025)

Lynozyfic linvoseltamab Updated Jul 6

What to watch

Lynozyfic is already approved and launching, so there's no binary event to trade. Investors should watch script trends and quarterly revenue disclosures for commercial uptake trajectory. The more relevant catalysts for REGN stock are the Dupixent expansion, EYLEA HD performance, and broader pipeline readouts, not Lynozyfic individually.

Bull case
  • 70% objective response rate and 45% complete response rate in heavily pretreated patients from the LINKER-MM1 trial is competitive with or better than Tecvayli (63%) and Elrexfio (56%) in their respective trials (source: pharmaceutical-technology.com)
  • Response-adapted dosing, monthly infusions after 24 weeks, is a convenience edge over competitors that require more frequent dosing, potentially driving physician preference (source: fiercepharma.com)
  • BMO analysts model ~$600M in potential peak Lynozyfic revenues, and Regeneron has initiated 10 registrational trials for the drug, suggesting significant label-expansion ambition into earlier treatment lines (source: biospace.com)
Bear case
  • Already three years behind J&J's Tecvayli (approved 2022, $549M 2024 sales) and two years behind Pfizer's Elrexfio ($133M 2024 sales) in a competitive BCMA bispecific space (source: fiercepharma.com)
  • Accelerated approval requires a confirmatory trial (LINKER-MM3), if that trial fails to verify clinical benefit, the FDA could withdraw the indication, creating long-term downside risk (source: natlawreview.com)
  • Regeneron's overall Q1 2026 revenue grew 19% to $3.6B, but EPS declined to $6.99 from $7.58, Lynozyfic's contribution is too small to move the needle for a company of this scale (source: simplywallst.com via search results)
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (since October 2020). Maftivimab monotherapy for BDBV is at the preclinical/investigational stage with no defined timeline.

maftivimab Updated Oct 26

What to watch

INMAZEB is already approved and commercialized with no upcoming PDUFA or pivotal readout. The BARDA extension (~$270M through 2031) provides predictable, modest government revenue. The WHO-backed maftivimab monotherapy trials for Bundibugyo ebolavirus are an early-stage, non-binary catalyst, clinical data from those trials (if initiated) would be the next meaningful event, but no timeline has been announced. For a company of Regeneron's scale, INMAZEB is a negligible financial driver.

Bull case
  • BARDA contract extension announced Oct 26, 2026 provides ~$270M in predictable government revenue through 2031, validating ongoing U.S. government demand
  • WHO recommendation (May 2026) to prioritize maftivimab for Bundibugyo ebolavirus clinical trials could open a new indication if successful
  • Preclinical data (bioRxiv, Oct 2026) shows maftivimab monotherapy is effective against Bundibugyo ebolavirus in non-human primate models
Bear case
  • INMAZEB is a negligible revenue contributor within Regeneron's $14B+ portfolio, not broken out in earnings, dwarfed by Dupixent, EYLEA HD, and Libtayo
  • No pending regulatory binary catalyst; the defining approval event occurred in 2020
  • Synapse database lists maftivimab's global R&D status as 'Discontinued', the monotherapy development program may have been shelved before the WHO recommendation revived interest
● neutral
Impact
PhaseApproved (EU), Phase 3 ongoing globally
Time to marketApproved in EU (Aug 2024) and launching commercially; US timeline unknown after two CRLs

Ordspono odronextamab Updated Jul 6

What to watch

For REGN investors, Ordspono is a non-binary minor commercial asset. The EU launch is underway but sales are small relative to Regeneron's scale. The US path is unclear after two FDA rejections (enrollment timelines, then manufacturing). Watch for: (1) any announcement of a third BLA resubmission, (2) Olympia-3 Part 1B data at ASCO/ASH, and (3) whether EU conditional marketing renewal faces any hurdles.

Bull case
  • First-in-class approval in EU validates the drug's efficacy and safety profile, Phase 2 data showed 80.5% overall response rate and 74.2% complete response rate in FL (source: LinkedIn/EHA2025 post citing Phase II results).
  • Olympia-3 Phase 3 data in first-line DLBCL (combo with CHOP chemo) has shown promising early efficacy with durable responses, potentially opening a much larger market beyond the current r/r label (source: ASCO 2026 abstract via ascopubs.org).
  • GlobalData analyst consensus forecasts $569M in total global sales by 2030, a meaningful commercial asset for Regeneron's oncology pipeline (source: Pharmaceutical Technology).
Bear case
  • FDA has rejected the drug twice, in Mar 2024 (confirmatory trial enrollment) and Aug 2025 (Catalent manufacturing site inspection), with no announced plan for a third resubmission, making US commercialization timeline highly uncertain (source: Cancer Network).
  • Intensely competitive market: Roche's Lunsumio (mosunetuzumab) and Columvi (glofitamab) plus AbbVie/Genmab's Epkinly (epcoritamab) are already approved in both the US and EU for similar lymphoma indications (source: BioPharma Dive).
  • Ordspono is a small contributor for Regeneron, the company's Q1 2026 revenue was $3.6B driven primarily by Dupixent ($4.34B/qtr global sales recorded by Sanofi) and Eylea. Even $569M peak sales would be <4% of total revenue (source: Regeneron Q1 2026 earnings via Finviz).
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched as of August 19, 2026.

Pasatru garetosmab-grts Updated Oct 30

What to watch

Pasatru is already approved and launching commercially; the next catalyst is the start of the Phase 3 OPTIMA 2 pediatric/adolescent trial (planned for later 2026), which would expand the addressable population but is not a binary event. Watch Q3 2026 earnings (today, Oct 30) for initial Pasatru sales commentary and any updates on OPTIMA 2 enrollment timing. For a company with ~$89B market cap and $4.3B quarterly revenue, Pasatru is a small but strategically important rare-disease franchise builder.

Bull case
  • First and only FDA-approved treatment that reduces both new heterotopic ossification lesions AND flare-ups in adult FOP, offering a differentiated mechanism vs oral competitor Sohonos. Phase 3 OPTIMA data showed zero new HO lesions from weeks 56 to 84 in the extension, demonstrating sustained disease control. The 84-week results were published in The Lancet (October 2026) and presented at ASBMR, adding strong peer-reviewed evidence. Annual pricing of $693K-$2.1M per patient positions Pasatru as a high-value ultra-orphan drug, and the planned OPTIMA 2 pediatric trial could expand the addressable population. Multiple analyst upgrades and price target raises in Q4 2026 reflect growing confidence in Regeneron's pipeline.
Bear case
  • Ultra-rare FOP affects only ~900 US patients, capping peak sales potential even at high pricing. Competition from Ipsen's Sohonos (palovarotene, oral) and Atebrioz creates a three-way market for a tiny patient pool. Skin and soft tissue infections (abscesses, cellulitis) occurred in 65% of patients on the 10 mg/kg dose vs 33% on placebo, a safety signal that could limit uptake. At ~$1.4M average annual list price, payer access and reimbursement hurdles are significant for an ultra-orphan infused biologic. Pasatru is a tiny fraction of Regeneron's ~$17B+ annual revenue, so even strong sales would have minimal impact on the stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since July 2015

Praluent alirocumab Updated Jul 6

What to watch

Praluent is a mature, marketed product that is unlikely to drive material share-price moves for REGN on its own. Investors should instead focus on Regeneron's much larger value drivers: Dupixent (the biggest growth engine), EYLEA HD (eye disease), and the broader pipeline. The key risk to watch for Praluent specifically is biosimilar entry as key patents expire, but even disruption there would be a rounding error for REGN's top line.

Bull case
  • Praluent is a commercially established, approved drug with a growing label, the March 2024 pediatric HeFH expansion opened a new patient population (source: Regeneron press release via investor.regeneron.com)
  • The global revenue trajectory is positive: Pharmacompass estimates 2025 global sales of ~$624M, up ~20% from ~$501M in 2024 (source: pharmacompass.com)
  • The long-running Amgen patent dispute was settled in March 2026, removing a major overhang and litigation uncertainty (source: juve-patent.com)
Bear case
  • Praluent is a minor product for Regeneron, US Q1 2026 net sales of ~$56.8M represent well under 1% of the company's $14.3B total 2025 revenue, making it nearly irrelevant to the investment thesis (source: finviz.com, Regeneron FY2025 earnings)
  • Praluent is the #2 PCSK9 player with roughly half the prescription volume of Amgen's Repatha (~7K vs ~14K weekly Rx), indicating persistent market share disadvantage (source: biopharmadive.com citing IQVIA data)
  • Key US patents are reportedly expiring around 2025, opening the door to biosimilar competition that could erode pricing and sales (source: drugpatentwatch.com)
◆ mixed
Impact
PhasePhase 1/2
Time to marketSeveral years from potential approval. Regeneron is enrolling a potentially registrational single-arm cohort, plans FDA discussions in the coming months, and intends to initiate a confirmatory randomized Phase 3 trial; even under an accelerated path, market entry would likely be several years away.

ubamatamab Updated Oct 30

What to watch

Watch for updates on the potentially registrational LGSOC cohort enrollment completion and any FDA meeting outcomes regarding the regulatory path. The next major catalyst would be data from the ~100-patient single-arm registrational cohort or the initiation of the planned confirmatory Phase 3 trial, though no specific date has been set.

Bull case
  • 73% objective response rate and 11-month median progression-free survival at 800 mg in heavily pretreated recurrent LGSOC, a cancer with limited options and generally poor chemotherapy response
  • Regeneron is enrolling a potentially registrational single-arm cohort of up to 100 patients at the 800 mg dose, which could support an accelerated approval path if data hold up
  • MUC16 is a novel therapeutic target; LGSOC has uniformly high MUC16 expression, and ubamatamab appears to work without biomarker selection
Bear case
  • Early data rests on only 11 evaluable patients (73% ORR, 8 of 11), a very small sample that could shrink in the larger ~100-patient cohort
  • Regeneron is a large-cap diversified biotech whose value spans Dupixent, Eylea, Libtayo and many other programs, so ubamatamab is a minor pipeline component and even a positive readout is a modest stock catalyst
  • Ovarian cancer is a crowded and competitive field: AbbVie's Elahere (mirvetuximab) is already approved in platinum-resistant disease, and other bispecifics/ADCs are in development
● neutral
Impact
PhasePhase 2
Time to marketAt least 4-6 years away, if successful. Both Phase 2 trials are complete but results have not been disclosed, and no Phase 3 trials have been registered. The drug would need positive Phase 2 data, Phase 3 trials, and FDA review before any potential approval.

baloncibart Updated Oct 30

What to watch

Watch for potential disclosure of Phase 2 topline results from either the POTS (PINNACLE) or sepsis (ESTELLA) trial, possibly at a future medical conference or in Regeneron's quarterly earnings materials. Positive results could support advancement to Phase 3, but given Regeneron's size and pipeline breadth, even a clear readout is unlikely to move the stock more than a few percent.

Bull case
  • First-in-class mechanism targeting NPR1, a novel approach for hypotensive disorders with no approved therapies specifically for POTS
  • Phase 1 data showed durable blood pressure increases of 5-10 mmHg with good tolerability, supporting the mechanism
  • Both Phase 2 trials have completed enrollment and data collection, meaning results could be disclosed at any time
Bear case
  • Both Phase 2 trials completed months ago (April and July 2026) but Regeneron has not disclosed any topline results, which could suggest underwhelming efficacy
  • Baloncibart is a very small program within Regeneron's massive pipeline (Dupixent, EYLEA HD, Libtayo, cemdisiran, etc.), so even positive data would have minimal impact on the stock
  • No Phase 3 trials registered, meaning the drug is likely years away from any potential approval or regulatory catalyst
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval October 2020)

Inmazeb atoltivimab/maftivimab/odesivimab Updated Oct 26

What to watch

Inmazeb has no upcoming binary catalyst, it is already approved and commercialized via episodic government contracts. The October 26, 2026 BARDA extension (~$270M through 2031) is the most recent news, but this is a multi-year supply deal, not a stock-moving event. Watch for future Ebola outbreak-related procurement announcements or WHO guideline updates, but Inmazeb is too small a piece of Regeneron's ~$80B market cap to drive meaningful share-price moves on its own.

Bull case
  • First and only FDA-approved Ebola treatment (alongside Ebanga), with a strong efficacy signal from the PALM trial showing ~35% relative mortality reduction vs control.
  • BARDA extended its procurement agreement on October 26, 2026, for ~$270 million through 2031, providing a visible, long-term government revenue stream.
  • WHO guidelines recommend Inmazeb as one of two preferred monoclonal antibodies for Ebola, supporting international adoption and outbreak-response procurement.
Bear case
  • Inmazeb revenue is episodic, undisclosed, and negligible relative to Regeneron's ~$14.3B total revenue, it is a rounding error vs Dupixent, Eylea, and Libtayo.
  • Ebola outbreaks are sporadic and unpredictable; the drug's commercial value depends entirely on government stockpiling and outbreak response, not recurring patient demand.
  • Competitor Ebanga (ansuvimab, Ridgeback Biotherapeutics) was also approved in December 2020 and is recommended alongside Inmazeb by WHO, splitting the addressable market.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since May 2017 (RA); latest label expansion (pJIA) approved June 2024

Kevzara sarilumab Updated Jul 6

What to watch

Kevzara is a steadily growing but non-blockbuster commercial drug for Regeneron. It contributes to Sanofi collaboration revenue but is dwarfed by Dupixent (~$17.8B global sales vs Kevzara's ~$600M). Investors should focus on Regeneron's bigger catalysts: the August 2026 PDUFA for garetosmab (FOP) and Dupixent label expansions, not Kevzara.

Bull case
  • Steady double-digit sales growth: Kevzara global sales grew ~27% to ~$601M in 2025, per Sanofi-reported figures, driven by label expansions into PMR and pJIA.
  • First-to-market advantage in PMR: Kevzara is the first and only FDA-approved biologic for polymyalgia rheumatica, a condition with no prior biologic options, giving it a unique niche.
  • No near-term biosimilar threat: Patent protection for sarilumab extends into the mid-to-late 2030s, with no biosimilars currently in development or approaching market.
Bear case
  • Far below early expectations: Initially forecast to reach $1B+ in peak sales, Kevzara generated only ~$600M globally in 2025, well short of blockbuster status.
  • Dominated by Actemra: Roche's tocilizumab (Actemra) is the established IL-6 inhibitor market leader with broader indications and longer commercial history, limiting Kevzara's market share in RA.
  • Highly diluted in Regeneron's portfolio: At ~$600M in global sales, Kevzara is roughly 3% the size of Dupixent ($17.8B), making it a non-material stock driver for REGN.
● neutral
Impact
PhasePhase 2
Time to marketTrevogrumab is in Phase 2 development with no Phase 3 trial or regulatory filing announced. If a Phase 3 program begins in 2027, potential approval would likely be several years away, assuming positive results.

trevogrumab Updated Oct 30

What to watch

The next catalyst for trevogrumab is Regeneron's planned Phase 2 trial in older adults with obesity and decreased muscle mass/strength, but no start date has been announced. Investors should watch for trial initiation and any partnership or licensing activity in the muscle-preservation space, as well as competitive developments from Eli Lilly's bimagrumab (Phase 3) and Scholar Rock's apitegromab. Trevogrumab is unlikely to drive material share-price moves for REGN in the next 12 months given the lack of a hard dated binary catalyst and the drug's small weight within Regeneron's diversified pipeline.

Bull case
  • Phase 2 COURAGE data showed trevogrumab preserved 42-71% of muscle normally lost on semaglutide, a clinically meaningful result in a large and growing GLP-1 market where muscle preservation is a key concern
  • The data were published in The Lancet and presented at EASD, signaling academic credibility and regulatory interest
  • Regeneron's VelocImmune platform gives it deep antibody expertise, and the company has the financial resources (Q3 2026 revenue of $5.1B) to advance the program without external funding
Bear case
  • Trevogrumab is still in Phase 2 with no Phase 3 trial or regulatory filing announced; the path to approval is long and uncertain
  • The myostatin inhibitor field has a history of failures: earlier candidates (MYO-029, domagrozumab, LY2495655) failed in sarcopenia, and Roche recently discontinued obesity development of its myostatin program
  • Competition is intensifying: Eli Lilly's bimagrumab is already in Phase 3 with tirzepatide, and Scholar Rock's apitegromab has Phase 2 data with tirzepatide, putting trevogrumab behind key rivals
● neutral
Impact
PhaseApproved
Time to marketAlready approved and on the market since August 2023

Veopoz pozelimab Updated Jul 6

What to watch

Veopoz is a very small commercial product (~$145-165M total market for CHAPLE disease) within Regeneron's $15B+ revenue base. For REGN investors, watch the pozelimab+cemdisiran combo program (ACCESS-1 for PNH, NIMBLE for gMG), those address much larger markets and are the real value driver for pozelimab as a molecule beyond Veopoz's approved niche.

Bull case
  • First and only FDA-approved treatment for CHAPLE disease, effectively no labeled competition (Soliris/Ultomiris used off-label).
  • As a C5 inhibitor, pozelimab is part of Regeneron's broader complement franchise; the poze-cemdi combination showed superiority over ravulizumab (Ultomiris) in Phase 3 PNH head-to-head data.
  • Regeneron is a commercial powerhouse with deep rare-disease experience, strong reimbursement, patient-support programs (myRARE), and manufacturing infrastructure already in place.
Bear case
  • Extremely small commercial opportunity, fewer than 100 patients worldwide, so Veopoz contributes immaterially to Regeneron's ~$15B+ annual revenue.
  • Competing C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab) from Alexion/AstraZeneca are established and used off-label for CHAPLE, creating some competition.
  • The Phase 2/3 approval was based on a small single-arm open-label study (n=10), no randomized controlled data.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

22 events
DateDrugEvent1 day5 days
Aug 1, 2026PasatruPDUFA decision−0.4%+2.9%
Apr 1, 2026EYLEA HDPDUFA decision−1.4%−0.6%
Apr 1, 2026OtarmeniAccelerated approval−1.4%−0.6%
Apr 1, 2026CemdisiranNDA filed−1.4%−0.6%
Apr 1, 2026EYLEA HDApproval−1.4%−0.6%
Feb 1, 2026DupixentApproval+1.8%+5.9%
Feb 1, 2026PasatruPriority review+1.8%+5.9%
Jan 31, 2026EYLEA HDNDA filed+1.8%+5.9%
Jan 1, 2026CemdisiranNDA filed+0.6%+3.8%
Dec 31, 2025EYLEA HDPDUFA decision+0.3%+3.5%
Dec 1, 2025EYLEA HDApproval−4.9%−9.9%
Nov 30, 2025EYLEA HDPDUFA decision−3.9%−7.9%
Nov 1, 2025EYLEA HDApproval−1.5%+0.9%
Oct 25, 2025EYLEA HDComplete response letter+1.3%+12.8%
Oct 1, 2025LibtayoApproval+6.7%+0.3%
Aug 18, 2023EYLEA HDApproval+6.0%+4.2%
Feb 11, 2021EvkeezaApproval−1.1%−4.2%
Oct 14, 2020InmazebApproval−3.8%−5.8%
Sep 28, 2018LibtayoApproval−2.9%−3.5%
Mar 28, 2017DupixentApproval+2.7%−0.2%
Jul 24, 2015PraluentApproval−3.0%−0.5%
Nov 18, 2011EYLEA HDApproval+7.6%+12.2%

Clinical trials

37 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
EYLEA HDEfficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationPhase 3Active not recruiting311Dec 22, 2026
REGN7999A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the BodyPhase 2Active not recruiting19Dec 3, 2026
LibtayoA Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaPhase 2Active not recruiting151Nov 2, 2026
DupixentStudy to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Phase 3Completed880Oct 9, 2026
VeopozA Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentPhase 3Completed202Sep 28, 2026
DupixentA Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisPhase 2Terminated18Aug 18, 2026
REGN7041A Study of REGN7041 for Active Noninfectious Uveitis in Adult ParticipantsPhase 2Terminated1Jul 21, 2026
mibavademabA Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)Phase 3Completed9Jul 9, 2026
OrdsponoA Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesPhase 2Active not recruiting515Jul 6, 2026
PasatruA Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationPhase 2Completed1,005Jun 16, 2026
baloncibartStudy of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)Phase 2Completed82May 6, 2026
REGN5713Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen AllergyPhase 3Terminated24May 2, 2026
Aspirin ChallengeMechanisms of Dupilumab in AERDPhase 2Completed16Apr 20, 2026
REGN9933A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)Phase 2Completed195Mar 27, 2026
baloncibartA Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced HypotensionPhase 2Completed76Feb 1, 2026
LibtayoGemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)Phase 2Terminated · results1Jan 5, 2026
DupixentDupilumab_Metastatic NSCLCPhase 2Completed33Sep 11, 2025
PraluentEffect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)Phase 3Completed118Aug 24, 2025
PraluentCardiac Allograft Vasculopathy Inhibition With AlirocumabPhase 2Completed · results114Jul 11, 2025
REGN5381REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge PressurePhase 2Completed · results59Jun 2, 2025
DupixentStudy to Assess Efficacy and Safety of Dupilumab in the Treatment of KeloidsPhase 2Completed · results20May 19, 2025
REGN1908A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat AllergyPhase 3Completed64May 10, 2025
REGN5459First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)Phase 2Completed43May 1, 2025
REGN5713A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen AllergyPhase 3Completed54Apr 23, 2025
LibtayoStudy of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 3Completed · results712Apr 18, 2025
EYLEA HDComparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1Phase 3Terminated16Mar 26, 2025
REGN2810Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerPhase 3Completed · results789Feb 27, 2025
DupixentGrass Pollen Immunotherapy Plus Dupilumab for Tolerance InductionPhase 2Completed · results199Feb 20, 2025
Sub-tenon injection of saline followed by a sub-tenon injection of afliberceptAnti-VEGF Therapy for Acute Thyroid Eye DiseasePhase 2Terminated · results8Dec 17, 2024
REGN7508A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult ParticipantsPhase 2Completed · results179Nov 19, 2024
LibtayoA Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerPhase 2Terminated · results77Oct 31, 2024
CMP-001CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaPhase 3Terminated · results20Jul 22, 2024
DupixentA Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous PemphigoidPhase 3Completed · results106Jul 12, 2024
EYLEA HDStudy to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)Phase 3Completed · results35May 31, 2024
LibtayoA Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell CarcinomaPhase 2Completed · results95Feb 16, 2023
Low-Dose REGN4461Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyPhase 2Completed · results16Jan 5, 2022
casirivimab+imdevimabA Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and AdultsPhase 3Terminated · results—Not stated

1 newer trial for subscribers. See plans